Patients under both therapeutic regimens presented some adverse events, such as visual impairment, diarrhea, nausea and vomiting, pulmonary embolism, aspartate transaminase (AST)/alanine aminotransferase (ALT) elevation, neutropenia, lymphocytopenia, anemia, thrombocytopenia, peripheral edema, prolonged QT interval, interstitium lung disease/pneumonia, and hair loss (Table 4). The gene discussed is GPT; the disease is Decreased total neutrophil count.